Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Return on Equity (2016 - 2025)

Historic Return on Equity for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Q4 2025 value amounting to 0.75%.

  • Enanta Pharmaceuticals' Return on Equity rose 1200.0% to 0.75% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.75%, marking a year-over-year increase of 1200.0%. This contributed to the annual value of 0.85% for FY2025, which is 1700.0% down from last year.
  • As of Q4 2025, Enanta Pharmaceuticals' Return on Equity stood at 0.75%, which was up 1200.0% from 1.14% recorded in Q3 2025.
  • Enanta Pharmaceuticals' Return on Equity's 5-year high stood at 0.2% during Q1 2021, with a 5-year trough of 1.14% in Q3 2025.
  • Its 5-year average for Return on Equity is 0.58%, with a median of 0.55% in 2023.
  • The largest annual percentage gain for Enanta Pharmaceuticals' Return on Equity in the last 5 years was 1200bps (2025), contrasted with its biggest fall of -3300bps (2025).
  • Enanta Pharmaceuticals' Return on Equity (Quarter) stood at 0.29% in 2021, then crashed by -32bps to 0.39% in 2022, then tumbled by -75bps to 0.68% in 2023, then dropped by -29bps to 0.87% in 2024, then grew by 14bps to 0.75% in 2025.
  • Its Return on Equity stands at 0.75% for Q4 2025, versus 1.14% for Q3 2025 and 1.06% for Q2 2025.